Afatinib CAS 439081-18-2 daahirnimo>99.5% (HPLC) Warshada

Afatinib, oo sidoo kale loo yaqaan BIW-2992, (CAS: 439081-18-2) waa jiilka labaad ee awoodda leh oo aan la beddeli karin ee xakameynaya korriinka koritaanka epidermal (EGFR) iyo receptor factor factor koritaanka epidermal 2 (HER2) tyrosine kinase, waxaa soo saaray Boehringer Ingelheim, Germany.Waxay awood u leedahay inay si aan leexleexad lahayn u joojiso dhaqdhaqaaqa tyrosine kinase iyada oo la marinayo falcelinta Michael ee kooxda thiol ee cysteine ​​ee booska 797 ee EGFR.Bishii Luulyo 12, 2013, waxay noqotay daawo cusub oo loogu talagalay kansarka sambabada unugyada yaryar ee ay ansixisay US FDA iyadoo hoos imanaysa magaca ganacsiga ee Gilotrif.Daawadani waa kaniin.Waxaa loo isticmaalaa daawaynta bukaanada laga helay kansarka sambabada unugyada aan yarayn ee metastatic (NSCLC) oo leh luminta 19th exon ama L858R mutation ee 21th exon of the epidermal growth factor receptor (EGFR) ayaa xaqiijiyay iyadoo la isticmaalayo qalabka la ansixiyay. by FDA.Daawadu waxay sidoo kale wax ku ool u tahay daaweynta bukaanka HER2-positive ee qaba kansarka naasaha ee sareeyo.Afatinib waxay ka tirsan tahay koox dawooyin ah oo loo yaqaanno tyrosine kinase inhibitors.Inhibitors Tyrosine kinase waxaa loogu talagalay inay xannibaan ficilka enzyme gaar ah oo loo yaqaan 'tyrosine kinase'.Insaymiskani waxa uu door weyn ka ciyaaraa shaqada unugyada,waxana uu si firfircoon u qaadaa kor u qaadida koritaanka iyo horumarka burada.Afatinib wuxuu u shaqeeyaa inuu joojiyo shaqada laba nooc oo ah tyrosine kinase: epidermal growth factor reseptor (EGFR) iyo Her2, kuwaas oo "si xad dhaaf ah u muujiyey" dhowr nooc oo kansar ah.Marka la xannibo shaqada tyrosine kinases, Afatinib waxa laga yaabaa inay ka hortagto unugyada kansarka inay qaybsadaan oo koraan.